Axsome Therapeutics

Axsome Therapeutics is a biopharmaceutical company developing novel therapies for the treatment of pain and other neurological diseases. By focusing on this therapeutic area, Axsome is addressing growing markets where current treatment options are limited or inadequate. Axsome has a balanced portfolio of clinical development stage as well as research stage products.

Axsome Therapeutics aims to become a fully integrated biopharmaceutical company that develops and commercializes differentiated products which increase the armamentarium of caregivers and improve the lives of patients. While the focus of the company is on developing its internally derived product candidates, Axsome also evaluates potential in-licensing opportunities to supplement its current portfolio.

Type
Public
HQ
New York, US
Founded
2012
Size (employees)
22 (est)+100%
Axsome Therapeutics was founded in 2012 and is headquartered in New York, US

Key People at Axsome Therapeutics

Herriot Tabuteau

Herriot Tabuteau

Chief Executive Officer
Robert Niecestro

Robert Niecestro

VP, Head of Regulatory Affairs

Axsome Therapeutics Office Locations

Axsome Therapeutics has office in New York
New York, US

Axsome Therapeutics Metrics

Axsome Therapeutics Summary

Market capitalization

$68.6 m

Closing share price

$4.4
Axsome Therapeutics's current market capitalization is $68.6 m.

Axsome Therapeutics Market Value History

Axsome Therapeutics Company Life

You may also be interested in